TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03249441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion-focused therapy
Description: Session-by-session summary of CFT:~Week 1: Understanding your relationship with food Week 2: Making sense of overeating Week 3: The Compassionate Mind/ Preparing your mind for compassion Week 4: Developing the skill of self-compassion Week 5: Why we overeat - a Compassionate approach Week 6: Understanding your current eating pattern Week 7: Motivating yourself to change Week 8: Determining what your body needs Week 9: Towards a new way of eating Week 10: Compassionate letter writing and developing a compassionate focus on eating.~__________________________________________________________________________
Study: NCT01045551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: 20mg taken orally twice per day for 12 weeks
Study: NCT02676050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical Imaging Agents (EMI-137, NAP)
Description: Both optical imaging agents (NAP and EMI-137) will be administered to each patient during a bronchoscopy procedure. A novel delivery catheter (to deliver both agents), imaging fibre and endomicroscopy system with viewer software will be used to detect c-MET and activated neutrophil signal in the human lung.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delivery Device Cathetar and Miniaturised imaging fibre
Description: Both optical imaging agents (NAP and EMI-137) will be administered and imaged simultaneously during a bronchoscopy procedure using the devices mentioned above.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical endomicroscopy system
Description: The signal emitted by both optical imaging agents (NAP and EMI-137) will be visualised using a novel endomicroscopy system.
Study: NCT01701349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosbretabulin + paclitaxel + carboplatin
Description: Fosbretabulin 200 mg/m2 IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + paclitaxel + carboplatin
Description: Paclitaxel 200 mg/m2, Carboplatin AUC 6 IV infusion
Study: NCT02300844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-0833
Description: Subjects will receive a single s.c. (subcutaneous/under the skin) dose of NNC0174-0833.~Up to nine dose levels of single s.c. doses of NNC0174-0833 are planned to be investigated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will receive a single s.c. (subcutaneousl/under the skin) dose.
Study: NCT00372294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pyrimethamine-sulfadiazine + prednisolone
Description: Administration of pyrimethamine-sulfadiazine + prednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin+Dexamethasone
Description: Intravitreal injection of Clindamycin+Dexamethasone
Study: NCT01565460

Intervention type: OTHER
Intervention: Sample Collection
Description: Sample Collection: bile and pancreatic duct brushings and fluid samples will be obtained from the pancreatic stricture during endoscopic retrograde cholangiopancreatic procedure.
Study: NCT00307892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traumeel S: intra-operative irrigation + oral ingestion
Description: homeopathic remedy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo remedy
Study: NCT03419351

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Smartphone
Description: Smartphone based measurement of refractive error and visual acuity testing using these measurements.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Autorefractor
Description: Autorefractor based measurement of refractive error and visual acuity testing using these measurements.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Individual
Description: Individual, human measurement of refractive error and visual acuity testing using these measurements.
Study: NCT04460300

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy-inhalation method
Description: In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is carried out through the essential oil inhalation method. Individuals who can distinguish odors in the odor sense test before the application is included in the study. Aromatherapy inhalation is applied for three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week. Intervention is made between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.~In this method, 5 drops of lavender oil will be dropped directly on a sterile gauze and individuals will be allowed to breathe from a distance of 10 cm for 5 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy-foot massage group
Description: In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is applied through foot massage. Swedish massage protocol is followed in foot massage intervention.The foot massage is performed on three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week.The intervention is performed between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.~Foot massage is done with 10 drops (5 drops per foot) of lavender for 10 minutes for each foot for 20 minutes. During the intervention, 20 techniques is used and the application time of each technique is 30 seconds (total 10 minutes per foot).
Study: NCT01449344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375mg/m² IV , day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375mg/m² IV , day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose Ara-C
Description: Ara-C 2000 mg/m² (patients \>65 years or s/p myeloablative treatment: 1000 mg/m²) IV, d 2 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Ara-C
Description: Ara-C 2000 mg/m² (patients \>65 years or s/p myeloablative treatment: 1000 mg/m²) IV, d 2 and 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 40 mg PO, day 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg PO, day 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.5 mg/m² IV, day 1 and 4
Study: NCT03006367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFC-1 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFC-1 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFC-1 400 mg
Study: NCT01984359

Intervention type: OTHER
Group type: OTHER
Intervention: Obtaining Human tissue
Study: NCT03990324

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual stretching
Description: Manual stretching for the upper trapezius and levator scapulae muscle
Study: NCT02432690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503
Description: BBI503 will be administered orally, once daily. Dosing will begin at 200 mg once daily, preferably at bedtime and 2 hours after a meal. Dose modification in case of adverse events is allowed according to the schedule below; Full dose: 200 mg daily, Modification Level-1: 100 mg daily, Modification Level-2: 50 mg daily.
Study: NCT04892394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information Types Before Endodontic Treatment
Description: The first aim of this study is to compare the effect of detailed video information or basic verbal information on the anxiety levels of patients by using anxiety scales before treatment. The second aim is to evaluate the effect of pretreatment video or verbal information on the stress level occurring in patients during the endodontic treatment steps by using electrodermal activity. The third aim is to investigate the relationship between patients' pretreatment anxiety levels and socio-demographic characteristics which are thought to play a role in anxiety's etiology.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information Types Before Endodontic Treatment
Description: The first aim of this study is to compare the effect of detailed video information or basic verbal information on the anxiety levels of patients by using anxiety scales before treatment. The second aim is to evaluate the effect of pretreatment video or verbal information on the stress level occurring in patients during the endodontic treatment steps by using electrodermal activity. The third aim is to investigate the relationship between patients' pretreatment anxiety levels and socio-demographic characteristics which are thought to play a role in anxiety's etiology.
Study: NCT03832166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruits and Vegetables
Description: Fruits and vegetables delivery, once/week for 24 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruits and Vegetables
Description: Fruits and vegetables delivery, once/week for 24 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooking
Description: Nutrition education and cooking instruction class, one class/week for 6 weeks
Study: NCT00510575

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal rod
Description: Posterior spinal fusion using a 5.5 or 6.35 size rod

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal rod
Description: Posterior spinal fusion using a 5.5 or 6.35 size rod
Study: NCT03289494

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balanced diet high in Slowly Digestible Starch
Description: The carbohydrate present in the diet high in Slowly Digestible Starch were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during one week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Balanced diet low in Slowly Digestible Starch
Description: The carbohydrate present in the diet low in Slowly Digestible Starch were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during one week.
Study: NCT00896350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Care Chemoradiation
Description: External beam radiation to the neck and tumor site of head and neck. Concurrent platinum based chemotherapy. External beam boost at discretion of treating physician.
Study: NCT01652222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CONEM-BETA + socio-educational training
Description: 4 socio-educative training sessions during 8 weeks, and caregivers will systematically play with their patients with CONEM-BETA therapeutic game during the last 4 weeks. The dyads will be assessed (primary timepoint). Caregivers will then continue using the game with their patients for an extra 6 weeks period as needed, to assess adherence and games preferences.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Socio-educational training only
Description: 4 socio-educative training sessions during 8 weeks
Study: NCT02336880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy
Study: NCT03327246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connecare self managment system
Description: The CONNECARE SMS will rely on a hybrid solution that, besides being autonomous (the patient may use the SMS to monitor and access to her/his data and information), has also a collaborative component (through the interaction with the SACM) to allow participation by clinicians and to provide feedback to them. In so doing, the patient may control her/his activity, receiving recommendations to improve the treatment and to be encouraged in following it.
Study: NCT00741767

Intervention type: DRUG
Group type: OTHER
Intervention: salmeterol-fluticasone
Description: 250ug salmeterol/50ug fluticasone inhaled via an oral inhaler twice daily

Intervention type: DRUG
Group type: OTHER
Intervention: salmeterol-fluticasone
Description: 250ug salmeterol/50ug fluticasone inhaled via an oral inhaler twice daily
Study: NCT01440972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: partial blood flow restriction (PBFR)
Description: low intensity resistance training with partial blood flow restriction 3 times/week for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low intensity resistance training
Description: low intensity resistance training without partial blood flow restriction
Study: NCT04447625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral antibiotic administration
Description: per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day for 14 days and metronidazole of 500mg twice a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral antibiotic administration
Description: per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day for 14 days and metronidazole of 500mg twice a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrauterine antibiotic infusion
Description: intrauterine infusion of 3ml of ciprofloxacin at a concentration of 200 mg/100 ml
Study: NCT00068822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty
Description: Placement of polymethylmethacrylate (PMMA) into vertebral compression fracture

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham vertebroplasty
Description: Participants, following local anesthesia with lidocaine and bupivacaine, were given verbal and physical cues such as pressure on the back, but the needle was not placed.
Study: NCT01495689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ottawa Model with SmartCard
Description: On-site counseling for Smoking Cessation along with the IVR automated telephone call follow-up and SmartCard worth $110 towards purchase of smoking cessation aids

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care or control arm will receive strong physician advice, brief counseling from clinic nurse +/- a prescription for smoking cessation aid if requested and willing
Study: NCT04409990

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Shear Wave Elastography
Description: SWE value of rectal lesions
Study: NCT01804647

Intervention type: OTHER
Intervention: No study treatments administered - blood draws only

Intervention type: OTHER
Intervention: No study treatments administered - blood draws only

Intervention type: OTHER
Intervention: No study treatments administered - blood draws only

Intervention type: OTHER
Intervention: No study treatments administered - blood draws only
Study: NCT03783013

Intervention type: OTHER
Group type: OTHER
Intervention: High Lycopene Tomato Juice With Soy Germ Extract
Description: Tomato juice made from high lycopene tomatoes with soy germ extract added

Intervention type: OTHER
Group type: OTHER
Intervention: Low Lycopene Tomato Juice
Description: Tomato juice made from low lycopene tomatoes with no soy germ extract added
Study: NCT02147106

Intervention type: OTHER
Intervention: Videoconsultation
Study: NCT00678249

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLAIR Endovascular Stent Graft
Description: Primary balloon angioplasty followed by placement of the FLAIR Endovascular Stent Graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PTA
Description: Percutaneous Transluminal Angioplasty

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLAIR Endovascular Stent Graft
Description: Primary PTA followed by placement of the FLAIR Endovascular Stent Graft. Roll-in participants were enrolled in the study for training purposes and were not randomized.
Study: NCT01166386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FANCI
Description: comprehensive neurobehavioral sessions with therapist administrating treatment components
Study: NCT03670693

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fMRI Exercise assessment
Description: Measurement of cardiac output and, cerebral and regional perfusion using Blood-Oxygen-level-dependent (BOLD) measures and arterial spin-labelling (ASL)-MRI as well as fractional oxygen extraction using TRUST-MRI during supine exercise of the quadriceps with the MR compatible cardiostepper (Ergospect, Innsbruck, Austria) at 50% of relative VO2 peak as measured during the supine cardiorespiratory fitness assessment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle deconditioning assessment
Description: Limb blood flow will be occluded with a cuff, whilst participants perform repeated plantar flexion exercise in a MRI scanner. This will drive PCr, (the available reserve of ATP) to zero. Once the cuff is removed, they will undergo non-invasive and well-established in vivo 31P magnetic resonance (31P MRS) measurements on the gastrocnemius to determine PCr re-synthesis rate during resting recovery.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle deconditioning assessment
Description: Limb blood flow will be occluded with a cuff, whilst participants perform repeated plantar flexion exercise in a MRI scanner. This will drive PCr, (the available reserve of ATP) to zero. Once the cuff is removed, they will undergo non-invasive and well-established in vivo 31P magnetic resonance (31P MRS) measurements on the gastrocnemius to determine PCr re-synthesis rate during resting recovery.
Study: NCT01166386

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: FANCI
Description: Watching DVDs chosen by participants on various topics.
Study: NCT01961128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Study: NCT03670693

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle deconditioning assessment
Description: Limb blood flow will be occluded with a cuff, whilst participants perform repeated plantar flexion exercise in a MRI scanner. This will drive PCr, (the available reserve of ATP) to zero. Once the cuff is removed, they will undergo non-invasive and well-established in vivo 31P magnetic resonance (31P MRS) measurements on the gastrocnemius to determine PCr re-synthesis rate during resting recovery.
Study: NCT00708773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 90 minute IV infusion once every 3 weeks.~Dose will be based on sex and genotype determination.
Study: NCT03792763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Description: Administration every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
Study: NCT04224350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TacroBell SR cap.
Description: * Orally, once-daily in the morning~* After first dose 0.2mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~12ng/ml for 0 to 3months and then at 3\~8ng/ml for 3 to 6months of study treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus cap.
Description: * Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment.
Study: NCT03542890

Intervention type: DEVICE
Intervention: Baska Mask
Description: used in adult low risk females undergoing elective gynecological operations

Intervention type: DEVICE
Intervention: I-gel
Description: used in adult low risk females undergoing elective gynecological operations
Study: NCT02162264

Intervention type: DRUG
Intervention: Donepezil Hydrochloride
Description: Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
Study: NCT02764086

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation
Description: Escalated dose of minimum 65Gy to the iGTV, with 60 Gy to PTV.
Study: NCT02935595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine Hydrochloride Injection
Study: NCT01654328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride tablets
Description: sodium chloride 1g/10kg of body weight /day per os on day -2 and -1 before contrast exposure. With a maximum dose of 10 gram sodium chloride a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline intravenously
Description: isotonic saline (Nacl 0.9%) total 1000ml in 4 hrs or (in case of heart failure or severe renal failure) 12 hrs before and in 4 or in 12 hrs after contrast administration.
Study: NCT04224987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin will be administered as a directly observed dose in oral suspension form for children:~1. Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~2. For children 1-11 months of age, weight or age-based dosing will be used~3. For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin will be administered as a directly observed dose in oral suspension form for children:~1. Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~2. For children 1-11 months of age, weight or age-based dosing will be used~3. For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a directly observed dose in oral suspension form for children:~1. Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~2. For children 1-11 months of age, weight-based dosing will be used~3. For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a directly observed dose in oral suspension form for children:~1. Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~2. For children 1-11 months of age, weight-based dosing will be used~3. For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program